Redx Pharma PLC Provides Updates on Lead Oncology Asset RXC004 Transcript
Redx Pharma's Andrew Saunders is with me today. Andrew, good to see you. How are you?
I'm very good. Thank you. How are you?
I'm doing well. Thanks, Andrew.
Questions & Answers
Could you recap for us your lead clinical program, RXC004? What's that program about?
So RXC004 is a small molecule that inhibits the porcupine on the Wnt pathway, which is an important enzyme on the Wnt pathway. The Wnt pathway is very important in tumor growth, both inhibiting tumor growth and in causing immune evasion. So by targeting the Wnt pathway with our porcupine inhibitor, we hope to, of course, cause tumor shrinkage and clinical benefits.
It's currently in Phase I, is it?
Yes. So we've gone through and are going through a classic dose escalation. We've completed 2 dose escalation cohorts, and we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |